606results about How to "Reduce occurrence" patented technology

The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.

The invention provides a multi-sensor system that uses an algorithm based on adaptive filtering to monitor a patient's respiratory rate. The system features a first sensor selected from the following group: i) an impedance pneumography sensor featuring at least two electrodes and a processing circuit configured to measure an impedance pneumography signal; ii) an ECG sensor featuring at least two electrodes and an ECG processing circuit configured to measure an ECG signal; and iii) a PPG sensor featuring a light source, photodetector, and PPG processing circuit configured to measure a PPG signal. Each of these sensors measures a time-dependent signal which is sensitive to respiratory rate and, during operation, is processed to determine an initial respiratory rate value. An adaptive digital filter is determined from the initial respiratory rate. The system features a second sensor (e.g. a digital 3-axis accelerometer) that attaches to the patient's torso and measures an ACC signal indicating movement of the chest or abdomen that is also sensitive to respiratory rate. This second signal is processed with the adaptive filter to determine a final value for respiratory rate.

A reduction-drive device has a first and a second reduction mechanism and distribution device. The first reduction mechanism has a planetary carrier, a planetary gear rotatably supported by the planetary carrier, an internal gear in mesh with the planetary gear and a sun gear. The first reduction mechanism is supported by the housing so as to reduce driving force of the electric motor. The second reduction mechanism is positioned between the electric motor and the first reduction mechanism so as to reduce an output of the first reduction mechanism. The differential device is supported by the housing so as to distribute the output of the second reduction mechanism to a wheel side.

An electronic apparatus (1) for control or training of an animal includes a housing (2) supported by a strap against the animal's skin, first and second stimulus probes (5) connected to a surface (9) of the housing, and control circuitry in the housing including output terminals selectively producing aversive stimulus. A stabilizing member (7) is connected to a location of the surface (9) of the housing that is offset from a straight line between the first and second stimulus electrodes (5) so that conductive tips of the first and second stimulus electrodes and a tip of the stabilizing post define a triangle, whereby the conductive tips of the first and second stimulus electrodes and the tip of the stabilizing member are pressed against the skin of the animal and prevent rocking of the conductive tips of the first and second stimulus electrodes against the skin of the animal to reduce the occurrence and/or severity of skin sores.

An electroplating solution contains a wetting agent in addition to a suppressor and an accelerator. In some embodiments, the solution has a cloud point temperature greater than 35° C. to avoid precipitation of wetting agent or other solute out of the plating solution. In some embodiments, the wetting agent decreases the air-liquid surface tension of the electroplating solution to 60 dyne/cm² or less to increase the wetting ability of the solution with a substrate surface. In some embodiments of a method for plating metal onto substrate surface, the electroplating solution has a measured contact angle with the substrate surface less than 60 degrees.

Methods are described for treating an influenza viral infection or associated diseases, disorders or mechanisms in a subject, comprising administering to the subject a therapeutically effective amount of a catecholic butane of the general formula (I) or a pharmaceutically acceptable salt thereof:

wherein R₁ and R₂ each independently represents a hydrogen, a lower alkyl, a lower acyl, an alkylene, or —OR₁ and —OR₂ each independently represents an unsubstituted or substituted amino acid residue or pharmaceutically acceptable salt thereof; R₃, R₄, R₅, R₆, R₁₀, R₁₁, R₁₂ and R₁₃ each independently represents a hydrogen, or a lower alkyl; and R₇, R₈ and R₉ each independently represents a hydrogen, —OH, a lower alkoxy, a lower acyloxy, an unsubstituted or substituted amino acid residue or pharmaceutically acceptable salt thereof, or any two adjacent groups together may be an alkyene dioxy; with the proviso in certain circumstances that where one of R₇, R₈ and R₉ represents a hydrogen, then —OR₁, —OR₂ and the other two of R₇, R₈ and R₉ do not simultaneously represent —OH.